Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€1.05
03.02.24
-
03.02.25
1.90%
17.02.24

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
Vivoryon Therapeutics N.V.

Start price
Target price
Perf. (%)
€8.35
02.02.24
-
02.02.25
0.60%
03.02.24

buy
Vivoryon Therapeutics N.V.

Start price
Target price
Perf. (%)
€8.37
01.02.24
-
01.02.25
0.36%
02.02.24

buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€1.06
26.12.23
-
26.12.24
-8.96%
11.01.24

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
CytoTools AG

Start price
Target price
Perf. (%)
€1.05
01.12.23
-
01.12.24
-64.57%
13.05.24

buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€0.90
11.11.23
-
11.11.24
-
11.11.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€0.81
05.11.23
-
05.11.24
15.43%
11.11.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€1.01
03.09.23
-
03.09.24
-19.80%
05.11.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
ifa systems AG

Start price
Target price
Perf. (%)
€3.16
20.08.23
€0.000
20.08.24
-5.70%
03.09.23

Revenue decline/stagnation expected
Decining EBIT margin than peer group
EBIT decline/stagnation expected
High valuation
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€1.28
06.08.23
-
06.08.24
-12.50%
20.08.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
Nanorepro AG

Start price
Target price
Perf. (%)
€2.17
09.05.23
-
09.05.24
-17.05%
10.05.24

buy
Nanorepro AG

Start price
Target price
Perf. (%)
€1.92
07.03.23
-
07.03.24
-11.37%
08.03.24

buy
ifa systems AG

Start price
Target price
Perf. (%)
€3.72
07.03.23
-
07.03.24
-27.42%
08.03.24

buy
Heidelberg Pharma AG

Start price
Target price
Perf. (%)
€4.89
26.02.23
-
26.02.24
-38.65%
27.02.24

CytoTools AG

Start price
Target price
Perf. (%)
€3.00
27.01.23
-
27.01.24
21.33%
05.02.23

CytoTools AG

Start price
Target price
Perf. (%)
€1.15
28.11.22
-
28.11.23
91.30%
24.04.23

Probably not worthwhile Investment
Eifelhoehen-Klinik

Start price
Target price
Perf. (%)
€3.00
26.11.22
€1.00
26.11.23
-3.33%
10.12.22

buy
Heidelberg Pharma AG

Start price
Target price
Perf. (%)
€5.52
21.10.22
-
21.10.23
-46.56%
22.10.23

buy
Heidelberg Pharma AG

Start price
Target price
Perf. (%)
€5.42
21.10.22
-
21.11.22
3.69%
22.11.22

buy
Heidelberg Pharma AG

Start price
Target price
Perf. (%)
€5.36
21.10.22
-
21.10.23
-8.77%
25.02.23

buy
ifa systems AG

Start price
Target price
Perf. (%)
€4.50
16.10.22
-
16.10.23
-15.56%
06.03.23

Eifelhoehen-Klinik

Start price
Target price
Perf. (%)
€2.90
01.10.22
€1.00
01.10.23
-3.45%
15.10.22

buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€3.72
07.08.22
-
07.08.23
-13.98%
26.08.22

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
Nanorepro AG

Start price
Target price
Perf. (%)
€3.97
27.07.22
€15.00
27.08.22
-14.12%
28.08.22

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
Very high dividend yield expected
Top 10 in its market
Eifelhoehen-Klinik

Start price
Target price
Perf. (%)
€2.80
23.07.22
€1.00
23.07.23
0.00%
06.08.22